Takeda Pharmaceutical Stock Forecast, Price & News

+0.05 (+0.30 %)
(As of 07/23/2021 11:38 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume37,862 shs
Average Volume1.52 million shs
Market Capitalization$53.21 billion
P/E Ratio14.92
Dividend Yield4.04%
30 days | 90 days | 365 days | Advanced Chart
Receive TAK News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Takeda Pharmaceutical logo

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.34 out of 5 stars

Medical Sector

852nd out of 2,216 stocks

Pharmaceutical Preparations Industry

403rd out of 866 stocks

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 3.3Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions

Is Takeda Pharmaceutical a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Takeda Pharmaceutical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TAK, but not buy additional shares or sell existing shares.
View analyst ratings for Takeda Pharmaceutical
or view top-rated stocks.

What stocks does MarketBeat like better than Takeda Pharmaceutical?

Wall Street analysts have given Takeda Pharmaceutical a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Takeda Pharmaceutical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Takeda Pharmaceutical?

Takeda Pharmaceutical saw a increase in short interest in June. As of June 30th, there was short interest totaling 9,410,000 shares, an increase of 66.5% from the June 15th total of 5,650,000 shares. Based on an average daily volume of 2,110,000 shares, the days-to-cover ratio is presently 4.5 days. Approximately 0.3% of the company's stock are sold short.
View Takeda Pharmaceutical's Short Interest

When is Takeda Pharmaceutical's next earnings date?

Takeda Pharmaceutical is scheduled to release its next quarterly earnings announcement on Friday, July 30th 2021.
View our earnings forecast for Takeda Pharmaceutical

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) announced its quarterly earnings data on Tuesday, May, 11th. The company reported $0.41 EPS for the quarter. The firm had revenue of $7.27 billion for the quarter. Takeda Pharmaceutical had a trailing twelve-month return on equity of 13.68% and a net margin of 11.77%.
View Takeda Pharmaceutical's earnings history

How has Takeda Pharmaceutical's stock been impacted by Coronavirus?

Takeda Pharmaceutical's stock was trading at $17.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TAK stock has decreased by 2.0% and is now trading at $16.81.
View which stocks have been most impacted by COVID-19

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical pays an annual dividend of $0.68 per share and currently has a dividend yield of 4.04%. TAK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio of Takeda Pharmaceutical is 34.34%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 72.34% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.
View Takeda Pharmaceutical's dividend history.

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the following people:
  • Mr. Christophe Weber, Pres, CEO & Representative Director (Age 55, Pay $8.61M)
  • Mr. Constantine Saroukos, CFO & Director (Age 50, Pay $4.53M)
  • Dr. Andrew S. Plump, Pres of R&D and Director (Age 56, Pay $5.1M)
  • Dr. Seigo Izumo, Chair of Management Board
  • Mr. Haruhiko Hirate, Member of Management Board (Age 64)
  • Salvatore Alesci, Member of Management Board and Head of R&D Global Science & Biomedical Policy
  • Mr. Iwaaki Taniguchi, Sr. VP of Corp. Fin. & Controlling Department
  • Mr. Christopher David O'Reilly, Global Head of Investor Relations & Global Fin.
  • Mr. Yoshihiro Nakagawa, Global Gen. Counsel (Age 61)
  • Ms. Mwana Lugogo, Chief Ethics & Compliance Officer (Age 51)

Who are some of Takeda Pharmaceutical's key competitors?

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a variety of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.01%) and Brookstone Capital Management (0.00%).

Which major investors are buying Takeda Pharmaceutical stock?

TAK stock was bought by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, and Brookstone Capital Management.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $16.81.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical has a market capitalization of $53.05 billion and generates $30.17 billion in revenue each year. The company earns $3.53 billion in net income (profit) each year or $1.98 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

Takeda Pharmaceutical employs 47,000 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?

The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.

When was Takeda Pharmaceutical founded?

Takeda Pharmaceutical was founded in 1781.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is www.takeda.com.

Where are Takeda Pharmaceutical's headquarters?

Takeda Pharmaceutical is headquartered at 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The company can be reached via phone at 813-3278-2111.

This page was last updated on 7/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.